Effectiveness and safety of olanzapine in the treatment of schizophrenia among Asian patients switching from conventional antipsychotics

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 31, Issue 1, 2007, Pages 32-40

  Lu, Zheng ^a   Hu, Jian ^b   Chen, Chih Ken ^c   Lan, Tsuo Hung ^d   Diokno Jr , Gregorio L ^e   Lee, Byoung Yong ^f   McElroy, Heather ^g   Harrison, Gavan ^g   Ang, Qiuqing ^h  

^a TONGJI UNIVERSITY   (China)

^b HARBIN MEDICAL UNIVERSITY   (China)

^c CHANG GUNG UNIVERSITY   (Taiwan)

^d Yuli Hospital Department of Health Taiwan   (Taiwan)

^e Institute of Urology   (Philippines)

^f Chuncheon National Hospital   (South Korea)

^g Intercontinental Information Sciences   (Australia)

^h Eli Lilly Asia Inc   (China)

Author keywords

Asia; Olanzapine; Quality of life; Safety; Schizophrenia; Treatment effectiveness

Indexed keywords

BENZODIAZEPINE DERIVATIVE; CHLORPROMAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE;

ABNORMAL INVOLUNTARY MOVEMENT SCALE; ADULT; ARTICLE; ASIAN; BRIEF PSYCHIATRIC RATING SCALE; CHINA; CLINICAL PRACTICE; CLINICAL TRIAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; FEMALE; HONG KONG; HUMAN; INVOLUNTARY MOVEMENT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTPATIENT; PHILIPPINES; PROSPECTIVE STUDY; QUALITY OF LIFE; SCHIZOPHRENIA; SCORING SYSTEM; SIDE EFFECT; SOUTH KOREA; SYMPTOMATOLOGY; TAIWAN; TREATMENT RESPONSE; WEIGHT GAIN;

ADULT; ANTIPSYCHOTIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; BENZODIAZEPINES; DYSKINESIA, DRUG-INDUCED; FEMALE; HUMANS; MALE; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; QUALITY OF LIFE; SAMPLE SIZE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 33845888026     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2006.06.006     Document Type: Article

References (42)

1. American Psychiatric Association. DSM-IV. Diagnostic and statistical manual of mental disorders. fourth ed (1994), American Psychiatric Association, Washington 273-315
2. Basson B.R., Kinon B.J., Taylor C.C., Szymanski K.A., Gilmore J.A., and Tollefson G.D. Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol or risperidone. J Clin Psychiatry 62 (2001) 231-238
3. Binder R.L., and Levy R. Extrapyramidal reactions in Asians. Am J Psychiatry 138 (1981) 1243-1244
4. Bradford L.D. The ethnopharmacology of atypical antipsychotics. CNS Spectr 10 3 Suppl. 2 (2005) S6-S12
5. Chiu N.Y., Yang Y.K., Chen P.S., Chang C.C., Lee I.H., and Lee J.R. Olanzapine in Chinese treatment-resistant patients with schizophrenia: an open-label, prospective trial. Psychiatry Clin Neurosci 57 (2003) 478-484
6. Chong S.A., Remington G.J., Lee N., and Mahendran R. Contrasting clozapine prescribing patterns in the east and west?. Ann Acad Med Singap 29 (2000) 75-78
7. Chong M.Y., Tan C.H., Fujii S., Tang S.Y., Ungvari G.S., Si T., et al. Antipsychotic drug prescription for schizophrenia in East Asia: rationale for change. Psychiatry Clin Neurosci 58 (2004) 61-67
8. Costa e Silva J.A., Alvarez N., Mazzotti G., Gattaz W.F., Ospina J., Larach V., et al. Olanzapine as an alternative therapy for patients with haloperidol-induced extrapyramidal symptoms: results of a multicenter, collaborative trial in Latin America. J Clin Psychopharmacol 21 (2003) 375-381
9. Emsley R.A., Roberts M.C., Rataemane S., Pretorius J., Oosthuizen P.P., Turner J., et al. Ethnicity and treatment response in schizophrenia: a comparison of three ethnic groups. J Clin Psychiatry 63 (2002) 9-14
10. Essock S.M., Drake R.E., Frank R.G., and McGuire T.G. Randomized clinical trials in evidenced-based mental health care: getting the right answer to the right question. Schizophr Bull 29 (2003) 115-123
11. FDA [homepage on the Internet]. Rockville: FDA; c 2002 [updated 2002 April 4; cited 2003 September 20]. Report to Congress: Reports on Postmarketing Studies [FDAMA 130] [1 screen]. Available from:http://www.fda.gov/cber/fdama/pstmrktfdama130.htm.
12. Foster R.H., and Goa K.L. Risperidone: a pharmacoeconomic review of its use in schizophrenia. PharmacoEconomics 14 (1998) 97-133
13. Foster R.H., and Goa K.L. Olanzapine: a pharmacoeconomic review of its use in schizophrenia. PharmacoEconomics 15 (1999) 611-640
14. Frackiewicz E.I., Sramek J.J., Herrera J.M., Kurtz N.M., and Cutler N.R. Ethnicity and antipsychotic response. Ann Pharmacother 31 (1997) 1360-1369
15. Gureje O., Miles W., Keks N., Grainger D., Lambert T., McGrath J., et al. Olanzapine vs risperidone in the management of schizophrenia: a randomized double-blind trial in Australia and New Zealand. Schizophr Res 61 (2003) 303-314
16. Haro J.M., Edgell E.T., Novick D., Alonso J., Kennedy L., Jones P.B., et al. Effectiveness of antipsychotic treatment for schizophrenia: 6-month results of the Pan-European Schizophrenia Outpatient Health Outcomes (SOHO) study. Acta Psychiatr Scand 111 (2005) 220-231
17. Hopper K., and Wanderling J. Revisiting the developed versus developing country distinction in course and outcome in schizophrenia: results from ISoS, the WHO collaborative followup project. International Study of Schizophrenia. Schizophr Bull 26 (2000) 835-846
18. Ishigooka J., Murasaki M., Miura S., and Olanzapine Early-Phase II Study Group. Efficacy and safety of olanzapine, an atypical antipsychotic, in patients with schizophrenia: results of an open-label multicenter study in Japan. Psychiatry Clin Neurosci 55 (2001) 353-363
19. Ishigooka J., Inada T., and Miura S. Olanzapine versus haloperidol in the treatment of patients with chronic schizophrenia: results of the Japan multicenter, double-blind olanzapine trial. Psychiatry Clin Neurosci 55 (2001) 403-414
20. Jann M.W., Chang W.H., Lam Y.W., Hwu H.G., Lin H.N., Chen H., et al. Comparison of haloperidol and reduced haloperidol plasma levels in four different ethnic populations. Prog Neuro-psychopharmacol Biol Psychiatry 16 (1992) 193-202
21. Kurzthaler I., and Fleischhacker W.W. The clinical implications of weight gain in schizophrenia. J Clin Psychiatry 62 Suppl. 7 (2001) 32-37
22. Lam Y.W., Jann M.W., Chang W.H., Yu H.S., Lin S.K., Chen H., et al. Intra-and interethnic variability in reduced haloperidol to haloperidol ratios. J Clin Pharmacol 35 (1995) 128-136
23. Lee C.T., Conde B.J., Mazlan M., Visanuyothin T., Wang A., Wong M.M., et al. Switching to olanzapine from previous antipsychotics: a regional collaborative multicenter trial assessing 2 switching techniques in Asia Pacific. J Clin Psychiatry 63 (2002) 569-576
24. Lee E., Leung C.M., and Wong E. Atypical antipsychotics and weight gain in Chinese patients: a comparison of olanzapine and risperidone. J Clin Psychiatry 65 (2004) 864-866
25. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., et al. Effectiveness of antipsychotic drugs in patients with chronic schiozphrenia. N Engl J Med 353 (2005) 1209-1223
26. Lin K.M., Anderson D., and Poland R.E. Ethnicity and psychopharmacology: bridging the gap. Psychiatr Clin North Am 18 (1995) 635-647
27. Mauskopf J., Muroff M., Gibson P.H., and Grainger D.I. Estimating the costs and benefits of new drug therapies: atypical antipsychotic drugs for schizophrenia. Schizophr Bull 28 (2002) 619-635
28. National Institute of Clinical Excellence. Guidance on the use of newer (atypical) antipsychotic drugs for the treatment of schizophrenia. Technology Appraisal Guidance; Report no.43 (2002), National Institute for Clinical Excellence, London
29. National Institute of Mental Health. Clinical Global Impressions (CGI). In: Guy W. (Ed). ECDEU assessment manual for psychopharmacology (1976), US Department of Health, Education and Welfare, Bethesda 217-222
30. National Institute of Mental Health. Abnormal Involuntary Movement Scale (AIMS). In: Guy W. (Ed). ECDEU assessment manual for psychopharmacology (1976), US Department of Health, Education and Welfare, Bethesda 534-537
31. Overall J.E., and Gorham D.R. The Brief Psychiatric Rating Scale (BPRS): recent developments in ascertainment and scaling. Psychopharmacol Bull 24 (1988) 97-99
32. Pi E.H. Transcultural psychopharmacology: present and future. Psychiatry Clin Neurosci 52 (1998) S185-S187 [Suppl]
33. Revicki D.A., Genduso L.A., Hamilton S.H., Ganoczy D., and Beasley Jr. C.M. Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: quality of life and clinical outcomes of a randomized clinical trial. Qual Life Res 8 (1999) 417-426
34. Ritchie C.W., Chiu E., Harrigan S., Hall K., Hassett A., Macfarlane S., et al. The impact upon extra-pyramidal side effects, clinical symptoms and quality of life of a switch from conventional to atypical antipsychotics (risperidone or olanzapine) in elderly patients with schizophrenia. Int J Geriatr Psychiatry 18 (2003) 432-440
35. Ruiz P., Chu P., Sramek J., Rotavu E., and Herrera J. Neuroleptic dosing in Asian and Hispanic outpatients with schizophrenia. Mt Sinai J Med 63 (1996) 306-309
36. Tran P.V., Hamilton S.H., Kuntz A.J., Potvin J.H., Andersen S.W., Beasley Jr. C., et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 17 (1997) 407-418
37. Treatment of Schizophrenia. The expert consensus guidelines series. J Clin Psychiatry 60 Suppl.11 (1999) 3-80
38. Voruganti L., Cortese L., Owyeumi L., Kotteda V., Cernovsky Z., Zirul S., et al. Switching from conventional to novel antipsychotic drugs: results of a prospective naturalistic study. Schizophr Res 57 (2002) 201-208
39. Wells K.B. Treatment research at the crossroads: the scientific interface of clinical trials and effectiveness research. Am J Psychiatry 156 (1999) 5-10
40. World Health Organization. The ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines (1992), World Health Organization, Geneva
41. World Health Organization. WHOQOL-BREF: introduction, administration, scoring and generic version of the assessment, field trial version. Programme on Mental Health (1996), World Health Organization, Geneva
42. Zhang-Wong J., Beiser M., Zipursky R.B., and Bean G. An investigation of ethnic and gender differences in the pharmacodynamics of haloperidol. Psychiatry Res 81 (1998) 333-339